Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

~ Regulatory approval received from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201™ ~

Amsterdam, The Netherlands, April 3, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approval from the national authority in Belgium (the FAGG, the Federal Agency for Medicines and Health Products) to start its randomized, controlled, transatlantic Phase III clinical trial with ATIR101™ for acute leukemia (CR-AIR-009) in Belgium. In addition, the Company has received regulatory approval from the national authority in Germany (the PEI, the Paul-Ehrlich-Institute) to start its Phase I/II clinical trial with ATIR201™ for thalassemia (CR-BD-001). This follows after the previous Company announcement in February 2017 that the Phase III trial with ATIR101™ has been initiated following regulatory approval from the national authority in Canada, and from the previous Company announcement at the end of 2016 that it had initiated the Phase I/II trial with ATIR201™ after having obtained regulatory approval from the national authority in the United Kingdom.

Leave a comment

Your email address will not be published.